Evaluation of pGL1-TNF-α therapy in combination with radiation

Oncology Research

Volumn 10, Issue 7, 1998, Pages 379-387

  Li, Jun ^a   Andres, Melba L ^a   Fodor, Istvan ^a   Nelson, Gregory A ^a   Gridley, Daila S ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C6 glioblastoma; Gene therapy; Plasmid; Radiation; TNF ; TNF receptors

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ARTICLE; CELL CULTURE; CELL SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONFOCAL MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; GLIOMA; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; NASA DISCIPLINE RADIATION HEALTH; NON-NASA CENTER; NUDE MOUSE; PLASMID; RAT; TIME;

NASA DISCIPLINE RADIATION HEALTH; NON-NASA CENTER;

ANIMALS; CELL SURVIVAL; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GLIOMA; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; PLASMIDS; RADIOTHERAPY, COMPUTER-ASSISTED; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032241362     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. American Cancer Society. Cancer facts & figures - 1997. Atlanta, GA: American Cancer Society, Inc.; 1997:1-32.
2. Coia, L. R.; Moylan, D. J. Introduction to clinical radiation oncology, 2nd ed. Baltimore: Williams & Wilkins Co; 1994.
3. Leibel, S. A.; Sheline, G. E. Tolerance of the central and peripheral nervous system to therapeutic irradiation. Adv. Radit. Biol. 12:257-293; 1987.
4. Carswell, E. A.; Old, L. J.; Russel, R. L.; Green, G.; Williamson, B. An endotoxin induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72:3600-3670; 1975.
5. Old, L. J. Antitumor activity of microbial products and tumor necrosis factor. In: Bonavida, B.; Gifford, G. E.; Kircher, H.; Old, L. J., eds. Tumor necrosis factor/cachectin and related cytokines. Basel, Switzerland: S. Karger; 1988:7-19.
6. Hallahan, D. E.; Haimovitz-Friedman, A.; Kufe, D. W.; Fuks, Z.; Weichselbaum, R. R. The role of cytokines in radiation oncology In: DeVita, V. T.; Hellman, S.; Rosenberg, S. A., eds. Important advances in oncology 1993. Philadelphia: J. B. Lippincott Co.; 1993:71-80.
7. Hersh, E. M.; Metch, B. S.; Muggia, F. M.; Brown, T. D.; Whitehead, R. P.; Budd, G. T.; Rinehart, J. J.; Crawford, E. D.; Bonnet, J. D.; Behrens, B. C. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the southwest oncology group experience. J. Immunother. 10:426-431; 1991.
8. Pfreundschuh, M. G.; Steinmetz, H. T.; Tuschen, R.; Schenk, V.; Dichl, V.; Schaadt, M. Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur. J. Cancer Clin. Oncol. 25:379-388; 1989.
9. Eggermont, A. M. M.; Koops, H. S.; Klausner, J. M.; Kroon, B. B. R.; Schlag, P. M.; Lienard, D.; van Geel, A. N.; Hoekstra, H. J.; Meller, I.; Nieweg, O. E.; Kettelhack, C.; Ben-Ari, G.; Pector, J.-C.; Lejeune, F. J. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg. 224:756-765; 1996.
10. Rubin, B. Y.; Smith, L. J.; Hellerman, G. R.; Lunn, R. M.; Richardson, N. K.; Anderson, S. L. Correlation between anticellular and DNA-fraementation activities of TNF. Cancer Res. 48:6006-6010; 1988.
11. Yamauchi, N.; Karizana, H.; Watanabe, H.; Neda, H.; Maeda, M.; Nutsu, Y. Intracellular hydroxyl radical production induced by recombinant tumor necrosis factor. Cancer Res. 49:1671-1675; 1989.
12. Zimmerman, R. J.; Chan, A.; Leadon, S. A. Oxidative damage in murine tumor cells treated in vitro by recombinant human TNF. Cancer Res. 49:1644-1648; 1989.
13. Hellman, S,; Weichselbaum, R. R. Radiation oncology and the new biology. Cancer J. Sci. Am. 1:174-179; 1995.
14. Jarvis, W. D.; Grant, S.; Kolesnick, R. N. Ceramide and the induction of apoplosis (minireview). Clin. Cancer Res. 2:1-6; 1996.
15. Gridley, D. S.; Hammond, S. N.; Liwnicz, B. Effects of tumor necrosis factor-α and radiation on human tumor xenografts. Anticancer Res. 14:1107-1112; 1994.
16. Gridley, D. S.; Andres, M. L.; Garner, C.; Mao, X. W.; Slater, J. M. Evaluation of tumor necrosis factor-α and radiation efficacy in a human lung adenocarcinoma model. Oncol. Res. 8:485-493; 1997.
17. Gridley, D. S.; Archambeau, J. O.; Andres, M. L.; Mao, X. W.; Slater, J. M. Tumor necrosis factor-α enhances the anti-tumor effects of radiation against glioma xenografts. Oncol. Res. 9:217-227; 1997.
18. Bausch, H. H.; Pfizenmaier, K.; Schroder, M.; Nagel, G. A. Intralesional application of recombinant human tumor necrosis factor induces local tumor regression in patients with advanced malignancies. Eur. J. Cancer Oncol. 25:287-291; 1989.
19. Sersa, G.; Willingham, V.; Milas, L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int. J. Cancer 42:129-134; 1988.
20. Hallahan, D. E.; Yokes, E. E.; Rubin, S. J.; O'Brien, S.; Samuels, B.; Vijaykumar, S.; Kufe, D. W.; Phillips, R.; Weichselbaum, R. R. Phase I dose-escalation study of tumor necrosis factor-α and concomitant radiation therapy. Cancer J. 1:204-209; 1995.
21. Seung, L. P.; Mauceri, H. J.; Beckett, M. A.; Hallahan, D. E.; Hellman, S.; Weichselbaum, R. R. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 55:5561-5565; 1995.
22. Mauceri, H. J.; Hanna, N. N.; Wayne, J. D.; Hallahan, D. E.; Hellman, S.; Weichselbaum, R. R. Tumor necrosis factor-α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 56:4311-4314; 1996.
23. Song, Y. K.; Liu, F.; Chu, S.; Liu, D. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum. Gene Ther. 8:1585-1594; 1997.
24. Wolff, J. A.; Budker, V. Cationic lipid-mediated gene transfer. In: Sobol, R. E.; Scanlon, K. J., eds. The internet book of gene therapy. Stamford, CT: Appleton & Lange; 1995:65-73.
25. Wolff, J. A.; Malone, R. W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P. L. Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468; 1990.
26. Benda, P.; Lightfoot, J.; Sato, G.; Levine, L.; Sweet, W. Differentiated rat glial cell strain in tissue culture. Science 161:370-371; 1968.
27. Auer, R.; Del Maestro, R. F.; Andersen, R. A simple and reproducible experimental in vivo glioma model. Can. J. Neurol. 8: 325-331; 1981.
28. Earle, W. R.; Schilling, E. L.; Stark, T. H.; Straus, N. P.; Brown, M. F.; Shelton, E. Production of malignancy in vitro. IV. The mouse fibroblast cultures and changes seen in the living cells. J. Natl. Cancer Inst. 4:165-212; 1943.
29. Stewart, P. A.; Hayakawa, K.; Hayakawa, E.; Farrell; C. L.; Del Maestro, R. F. A quantitative study of blood brain barrier permeability ultrastructure in a new glioma model. Acta Neuropathol. (Berl.) 67:96-102; 1985.
30. Sheay, W.; Nelson, S.; Martinez, I.; Chu, T.-H. T.; Bhatia, S.; Dornburg, R. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. Biotechniques 15:856-862; 1993.
31. Tada, M.; Sawamura, Y.; Sakamura, S.; Suzuki, K.; Ohta, H.; Aida, T.; Abe, A. Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor a for the treatment of malignant gliomas. Cancer Immunol. Immunother. 36:251-259; 1993.
32. Yamasaki, T.; Moritake, K.; Paine, J. T.; Fukuda, M.; Ohta, F.; Naitoh, H. Intratumoral administration of tumor necrosis factor-alpha for malignant glioma - two case reports. Neurol. Med. Chir. Tokyo 34:216-220; 1994.
33. Tartaglia, L. A.; Ayres, T. M.; Wong, G. H.; Goeddel, D. V. A novel domain within the 55kd TNF receptor signals cell death. Cell 74:845-853; 1993.
34. Merrick, W. C. Mechanism and regulation of eukaryotic protein synthesis. Microbiol. Rev. 56:291-315; 1992.
35. Tartaglia, L. A.; Rothe, M.; Hu, Y.; Goeddel, D. V. Tumor necrosis factor's cytotoxic activity is signaled by the p55 receptor. Cell 73:213-216; 1993.
36. Natoli, G.; Costanzo, A.; Ianni, A.; Templeton, D. J.; Woodgett, J. R.; Balsano, C.; Levrero, M. Activation of SAPK/JNK by TNF receptor 1 through noncytotoxic TRAF2-dependent pathway. Science 275:200-203; 1997.
37. Shu, H.; Takeuchi, M.; Goeddel, D. V. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc. Natl. Acad. Sci. USA 93:13973-13978; 1996.
38. Weiss, T.; Grell, M.; Hessabi, B.; Bourteele, S.; Muller, G.; Scheurich, P.; Wajant, H. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80. J. Immunol. 158:2398-2404; 1997.